---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031805"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:09:08.697695+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "medium"
source: SEC EDGAR
---

# Clene presents RESTORE-ALS Phase 3 trial design for CNM-Au8 at NEALS meeting

## Summary
- Presented preliminary design for RESTORE-ALS, an international Phase 3 trial of CNM-Au8 30 mg for ALS.
- Presentation made at the 2024 Annual NEALS Meeting on October 23, 2024.
- No efficacy or safety results disclosed; only the trial design was shared.

## SEC filing metadata
- accession: 0001437749-24-031805
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774924031805/0001437749-24-031805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774924031805/clnn20241022_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031805
- JSON: https://secwatch.observer/filing/0001437749-24-031805.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.